SIGY SIGY

Sigyn Therapeutics (QB) Stock Price

0.20
0.00 (0.0%)
0.20
Volume 0.00
Bid Price 0.1472
Ask Price 0.2383
News -
Day High

Low
0.146

52 Week Range

High
1.00

Day Low
Company Name Stock Ticker Symbol Market Type
Sigyn Therapeutics Inc (QB) SIGY OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.20 08:02:39
Open Price Low Price High Price Close Price Prev Close
0.20
Trades Volume Avg Volume 52 Week Range
0 0.00 - 0.146 - 1.00
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.20 USD

Period:

Draw Mode:

Sigyn Therapeutics Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.46M 37.30M 8.63M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.60k $ - - - -

more financials information »

Sigyn Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SIGY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.19950.200.19950.19979191,6520.00050.25%
3 Months0.1460.2680.1460.23603052,6740.05436.99%
6 Months0.37990.380.1460.21879943,781-0.1799-47.35%
1 Year0.881.000.1460.42420944,388-0.68-77.27%
3 Years1.85013.500.1461.053,256-1.65-89.19%
5 Years1.85013.500.1461.053,256-1.65-89.19%

Sigyn Therapeutics (QB) Description

Sigyn Therapeutics, Inc, is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives. Sigyn Therapy is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.


Your Recent History
USOTC
SIGY
Sigyn Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now